[Articles] Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial

Journal content Created on 14 Jul 2026 The Lancet Oncology

• Details
• • All feed content
  • My feed content